BioWorld Asia

Nov. 2, 2005

View Archived Issues

Map Of Changes Promises To Unmask Multitude Of Genes

NicOx Licenses Respiratory Drug To Topigen For 54.9M

CAT Paying $14M In Shares For Genencor Cancer Drugs

Ark's Gene Therapy Product Cerepro Under Review In EU

AM-Pharma Gets 9M In First Closing Of Series B Round

Other News To Note

CAT, Abbott Settle Humira Dispute: Abbott Pays $255M

Ending a 2-year-old dispute, Cambridge Antibody Technology plc and Abbott Laboratories reached an agreement concerning Humira royalties payable to CAT under a 1995 deal. (BioWorld International) Read More

2005's Second German IPO Prices At Low End Of Range

Today's news in brief

BioWorld

BioWorld briefs for Dec. 24, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 24, 2025.

Illustration of magnifying glass looking at cancer in the brain

Researchers discover how glioblastoma tumors dodge chemotherapy

BioWorld MedTech

Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...

Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

HIV research is close to a cure but far from ending the pandemic

BioWorld

Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...

Illustration of tau accumulating in a neuron cell.

ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

BioWorld

ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...